ArticleCureus2026
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals With Type 2 Diabetes Using Vibration-Controlled Transient Elastography and Serial Elastography Measurements to Monitor Response to Therapy: Methodological Details.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn type 2 diabetic mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent diffuse liver disease. Although most people with MASLD do not progress to the cirrhotic stage, patients with T2DM appear to advance more quickly and are at higher risk of steatohepatitis and liver-related mortality. The fibrosis degree is the strongest predictor of both liver-specific and all-cause mortality. Due to these factors, it is essential to identify people with advanced fibrosis or those who are more likely to develop it among the vast population of people with MASLD.
methodsVibration-controlled transient elastography (VCTE) will be used to determine the existence and severity of MASLD in people with T2DM and to examine its relationship to glycemic management and comorbidities associated with diabetes.
resultsPrevalence of MASLD among patients with T2DM will be measured using VCTE as an imaging modality, and the different stages of MASLD will be correlated with other diabetes related complications.
conclusionsMASLD is a common liver disease in the diabetic population. Although Asians exhibit a considerably lower BMI and reduced obesity rates in contrast with other ethnic groups, they present an elevated prevalence of hypertension, diabetes, metabolic syndrome, and MASLD. This study is expected to estimate the prevalence of MASLD. A higher rate of MASLD is expected in diabetic individuals with poor glycemic control and who have other metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.